Introduction
Electronic cigarettes (ECs) that consist of a battery, heater, and nicotine-containing liquid are marketed as devices that deliver nicotine to the user. ECs have become increasingly popular , and some reports suggest that they help users quit or reduce cigarette smoking ( Ayers, Ribisi, & Brownstein, 2011 ; Etter, 2010 ; Etter and Bullen, 2011a ; Heavner, Dunworth, Bergen, Nissen, & Phillips, 2009 ; McQueen, Tower, & Sumner, 2011 ; Polosa et 
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later, blood was sampled , and 5 min after that, participants were provided with their EC and were instructed to take 10 puffs (30 -s interpuff interval [ IPI ; as in Eissenberg, 2010 ; Vansickel et al., 2010 ] ). Blood was sampled 5 and 15 min after the start of the 10-puff period. Then, a 60-min ad lib puffi ng period began , and blood was sampled every 15 min. Participants then entered a 2 -hr rest period during which no puffi ng occurred , and blood was sampled every 30 min. Participants completed subjective questionnaires at baseline and again after the 10-puff, ad lib , and rest periods. At session ' s end, the venous catheter was removed, physiological monitoring ceased, and participants were compensated.
Physiological outcome measures included heart rate (measured every 20 s) and plasma nicotine concentration (blood centrifuged and plasma stored at − 70 ° C for analysis of nicotine concentration). Subjective and behavioral outcome measures included the Tiffany -Drobes Questionnaire of Smoking Urges Brief (QSU Brief; Cox, Tiffany, & Christen, 2001 ) , 11 visual analogue scale (VAS) items that assessed nicotine/EC abstinence symptoms ( Kleykamp et al., 2008 ) , 10 VAS items that assessed the direct effects of nicotine ( Blank, Sams, Weaver, & Eissenberg, 2008 ) , 14 VAS items that assessed the direct effects of the EC ( Vansickel et al., 2010 ) as well as the total number of puffs taken during the ad lib period.
Results
Participants were former smokers who had tried to quit smoking an average ( SD ) of 3.9 (1.8) times in their lifetime, had quit smoking for 11.4 (5.4) months , and had been using ECs for 11.5 (5.4) months. Their average age was 33.4 (8.6) years , and they had completed 15.3 (2) years of education. Seven participants used devices that did not resemble tobacco cigarettes and housed higher voltage and/or longer lasting batteries than in previous work (e.g., Vansickel et al., 2010 ) . Six participants used 18 mg/ml nicotine solution, one used 9 , and the other used 24 mg/ml solution.
Plasma nicotine increased signifi cantly from a baseline mean of 2 ng/ml ( SEM = 0) to a mean of 10.3 ng/ml ( SEM = 2) within 5 min of the fi rst puff. Plasma nicotine reached a maximum mean concentration ( M = 16.3 ng/ml, SEM = 4.5) by the end of the ad lib period (see Figure 1 ; relative to baseline all P < .05 by paired t test). Heart rate increased signifi cantly from a baseline mean of 73.2 ( SEM = 2.0) beats per minute (bpm) to 78 ( SEM = 1.9) bpm within 5 min of the fi rst puff and remained elevated during the ad lib period. The number of puffs during the 1-hr ad lib period ranged from 4 to 76 ( M = 46.6, N = 7). VAS ratings of " Anxious " were elevated at baseline ( M = 13.9, SEM = 4.5), were signifi cantly reduced following the 10-puff ( M = 2.8, SEM = 2.5) and ad lib ( M = 0.9, SEM = 0.6) periods, and returned to baseline levels after the rest period ( M = 12.4, SEM = 4). VAS ratings of " Restlessness " were elevated at baseline ( M = 26, SEM = 9), were signifi cantly reduced following the ad lib period ( M = 4.8, SEM = 4), and increased following the rest period ( M = 8.8, SEM = 4) (see Figure 1 ) . Similarly QSU Factor 1 (intention to smoke) scores were elevated at baseline ( M = 21, SEM = 2.7), were significantly reduced following the ad lib puffing period ( M = 5.6, SEM = 1.9), and returned to baseline levels after the rest period ( M = 18.3, SEM = 2.2). Positive direct effects of EC administration were also observed. VAS ratings of Did the EC help you " Feel awake , " " Calm you down , " and " Concentrate " as well as Was the EC " Pleasant " and " Satisfying " and Did the EC " Reduce your hunger for food " and " Taste Good " increased signifi cantly following the 10-puff period, peaked following the ad lib period, and decreased after the rest period. For example, ratings of " Satisfying " increased from 0.125 ( SEM = 0.125) to 83.9 ( SEM = 7) after the 10-puff bout and further increased to 92.6 ( SEM = 3.3) following the ad lib period before dropping to 36.9 ( SEM = 13.5) after the rest period. EC use did not signifi cantly affect ratings on any other measure.
Discussion
Previous reports have described conditions of EC use that support minimal or no nicotine delivery ( Bullen et al., 2010 ; Eissenberg, 2010 ; Vansickel et al., 2010 ) . In those studies, current cigarette smokers, who were not experienced with ECs, engaged in brief periods of EC use. In addition, the ECs used in those studies were cigarette-sized EC models. In the current study, experienced EC users who provided their preferred ECs loaded with their selected fl avor/nicotine concentration completed a 10-puff (30 -s IPI) bout and a 1 -hr ad lib puffi ng period. Under these conditions, EC use resulted in reliable nicotine delivery. These results are the fi rst to demonstrate unequivocally that ECs alone are capable of increasing plasma nicotine concentrations to levels seen during cigarette smoking. In support of this conclusion, the results of a recent study in which the saliva cotinine
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concentration of self-reported EC users was measured are also consistent with nicotine exposure that approximated tobacco cigarette use (e.g., Etter & Bullen, 2011b ) . However, unlike the current laboratory study, results of this previous work may have been infl uenced by the concurrent use of other nicotine-containing products.
Interestingly, abstinence symptoms were observed prior to EC use , and these symptoms were suppressed after EC use, a potential indicator of nicotine dependence ( Carter and Griffi ths, 2009 ) . Of course, these participants were former cigarette smokers and thus may have been nicotine dependent prior to initiating EC use. The extent to which EC use leads to the development of nicotine dependence in nicotine-naïve users is unknown.
Some reports suggest that ECs have the potential to be safe and effi cacious replacements for tobacco cigarettes due to nicotine ' s effects ( Etter & Bullen, 2011a ; Siegel, Tanwar, & Wood, 2011 ) . That potential is undermined by ineffective devices and a requirement that users learn specifi c but as-yet-undetermined behaviors in order to maximize nicotine delivery. Thus, an important area for future research is the parametric manipulation of device characteristics and user behavior (i.e., puff topography) as well as other factors (e.g., nicotine concentration) that might contribute to safety and effi cacy. In addition, the potential deleterious health effects of chronic inhalation of vaporized nicotine solutions are unknown ( Etter, Bullen, Fouris, Laugesen, & Eissenberg, 2011 ) . Clinical laboratory evaluation of lung and cardiovascular function, measurement of biomarkers of harm (e.g. , infl ammatory biomarkers such as C-reactive protein) , as well as population level surveillance of adverse events associated with EC use will be necessary for ensuring safety and proper regulation. Taken together, results of the current and previous studies demonstrate considerable variability in EC nicotine delivery, device performance, and/or cartridge and vapor nicotine content ( Bullen et al., 2010 ; Eissenberg, 2010 ; U.S. Food and Drug Administration, 2009 ; Vansickel et al., 2010 ; . One important potential benefi t of EC regulation may be more consistent nicotine delivery, device performance, and cartridge and vapor content.
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